AT-101
Showing 1 - 25 of >10,000
B-cell Non Hodgkin Lymphoma Trial in Seoul (AT101(Anti-CD19 Chimeric Antigen Receptor T cell))
Recruiting
- B-cell Non Hodgkin Lymphoma
- AT101(Anti-CD19 Chimeric Antigen Receptor T cell)
-
Seoul, Korea, Republic ofAsan Medical Center
May 24, 2022
Laryngeal Cancer Trial in Ann Arbor (AT-101, Docetaxel, Cisplatin)
Completed
- Laryngeal Cancer
- AT-101
- +3 more
-
Ann Arbor, MichiganUniversity of Michigan Comprehensive Cancer Center
Dec 17, 2021
Bipolar Depression, Bipolar Affective Disorder Trial (NRX-101)
Available
- Bipolar Depression
- Bipolar Affective Disorder
- (no location specified)
Mar 22, 2023
Recurrent Plasma Cell Myeloma Trial in Jacksonville (Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide)
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Dexamethasone
- +4 more
-
Jacksonville, FloridaMayo Clinic in Florida
Jan 4, 2023
Peripheral T Cell Lymphoma (PTCL), Cell Therapy Trial in United States (MT-101, MT-101 + Conditioning (Lymphodepleting)
Recruiting
- Lymphoma, T-Cell, Peripheral
- +4 more
- MT-101
- MT-101 + Conditioning (Lymphodepleting) Chemotherapy
-
Duarte, California
- +8 more
Jan 27, 2023
Pompe Disease Trial in Saint Louis, New York, Durham (ACTUS-101)
Recruiting
- Pompe Disease
- ACTUS-101
-
Saint Louis, Missouri
- +2 more
May 25, 2022
Bariatric Surgery, Obesity, Weight Gain Trial in San Diego (ARD-101)
Recruiting
- Bariatric Surgery
- +2 more
-
San Diego, CaliforniaAltman Clinical and Translational Research Institute, University
Apr 21, 2022
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis Trial in United States (Biospecimen
Recruiting
- Recurrent Langerhans Cell Histiocytosis
- Refractory Langerhans Cell Histiocytosis
- Biospecimen Collection
- +8 more
-
Wilmington, Delaware
- +3 more
Apr 28, 2023
Cancer, Covid-19 Trial in Canada (IMM-101, Observation)
Active, not recruiting
- Cancer
- Covid-19
- IMM-101
- Observation
-
Hamilton, Ontario, Canada
- +7 more
Jun 23, 2022
Metastatic HER2 Positive Gastroesophageal Junction Cancer Trial in La Jolla, Washington, Hackensack (CYNK-101, Pembrolizumab,
Recruiting
- Metastatic HER2 Positive Gastroesophageal Junction Cancer
- CYNK-101
- +6 more
-
La Jolla, California
- +2 more
Jul 12, 2022
Sickle Cell Disease Trial in Birmingham, Palo Alto, Saint Louis (GPH101 Drug Product)
Active, not recruiting
- Sickle Cell Disease
- GPH101 Drug Product
-
Birmingham, Alabama
- +2 more
Jan 5, 2023
Prostatic Tumors, Castration-Resistant, Tumors by Histologic Type, Tumors, Prostate Trial in United States (P-PSMA-101 CAR-T
Active, not recruiting
- Prostatic Neoplasms, Castration-Resistant
- +16 more
- P-PSMA-101 CAR-T cells
- Rimiducid
-
Duarte, California
- +9 more
Nov 15, 2022
Breast Cancer, Colorectal Cancer, Ovarian Cancer Trial in United States (ATRC-101, Pembrolizumab, Pegylated liposomal
Recruiting
- Breast Cancer
- +15 more
- ATRC-101
- +2 more
-
Phoenix, Arizona
- +10 more
Sep 28, 2022
Coronary Artery Disease Trial in Reykjavik (A digital care solution for patients with Coronary Artery Disease, Standard of care
Recruiting
- Coronary Artery Disease
- A digital care solution for patients with Coronary Artery Disease
- Standard of care for patients with Coronary Artery Disease
-
Reykjavik, IcelandLandspítali University Hospital
Feb 8, 2023
Fluid Retention, Sodium Retention, Heat Stress Trial in Storrs (PR Lotion - AMP Human Performance, Placebo Lotion, AminoVital -
Recruiting
- Fluid Retention
- +5 more
- PR Lotion - AMP Human Performance
- +3 more
-
Storrs, ConnecticutKorey Stringer Institute at the University of Connecticut
May 19, 2022
Prader-Willi Syndrome Trial in Australia, Canada, United States (3.2 mg intranasal carbetocin, 9.6 mg intranasal carbetocin, )
Completed
- Prader-Willi Syndrome
- 3.2 mg intranasal carbetocin
- +2 more
-
Birmingham, Alabama
- +23 more
Jul 18, 2022
